Identification

Name
Mannitol
Accession Number
DB00742  (APRD01083, EXPT02246)
Type
Small Molecule
Groups
Approved, Investigational
Description

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.

Structure
Thumb
Synonyms
  • (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
  • (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
  • D-(-)-Mannitol
  • D-Mannitol
  • e 421
  • e421
  • Fraxinine
  • Manitol
  • Manna Sugar
  • Mannit
  • Mannite
  • Mannitol
  • Mannitolum
External IDs
E-421 / INS NO.421 / INS-421
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis2012-04-13Not applicableEu
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis2012-04-13Not applicableEu
MannitolInjection, solution5 g/100mLIntravenousHospira, Inc.1987-01-082016-11-16Us
MannitolInjection, solution12.5 g/50mLIntravenousHospira, Inc.1967-12-22Not applicableUs
MannitolInjection, solution20 g/100mLIntravenousB. Braun Medical Inc.1993-07-26Not applicableUs
MannitolInjection, solution15 g/100mLIntravenousHospira, Inc.1987-01-08Not applicableUs
MannitolInjection, solution10 g/100mLIntravenousHospira, Inc.1987-01-082016-11-16Us
MannitolInjection, solution12.5 g/50mLIntravenousCardinal Health2010-02-01Not applicableUs
MannitolInjection, solution20 g/100mLIntravenousHospira, Inc.1987-01-08Not applicableUs
MannitolIrrigant5 g/100mLIrrigationB. Braun Medical Inc.1978-02-10Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MannitolInjection, solution250 mg/mLIntravenousFresenius Kabi2000-03-19Not applicableUs
MannitolInjection, solution12.5 g/50mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
MannitolInjection, solution250 mg/mLIntravenousAmerican Regent1990-09-30Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GD11 Rx SCM C5Liquid.1 g/2mLTopicalCoson Co., Ltd.2017-07-01Not applicableUs
International/Other Brands
Anol (Astar) / Aridol (Pharmaxis) / Bronchitol (Pharmaxis) / Deltamannit (DeltaSelect) / Demanitol (Medifarma) / Diurecide (Lusa) / Isotol / Manicol / Manit (Pliva) / Manitol Mein (Fresenius) / Maniton / Mannigen / Mannisol (Human Co. Ltd.) / Mannisol A (Teva) / Mannit / Mannit-Lösung (Serag-Wiessner) / Mannite Actipharm (Actipharm) / Osmitrol / Osmofundin (B. Braun) / Osmohale (Pharmaxis) / Osmosol (Beximco) / Osmosteril (Fresenius) / Resectisol (B. Braun)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Additive Solution Sodium Adenine Glucose Mannitol (sagm)Mannitol (5.25 g) + Adenine (0.169 g) + Glucose (9 g) + Sodium Chloride (8.77 g)SolutionUnknownMaco Pharma2016-08-22Not applicableCanada
Cystosol W 3% HexitolsMannitol (500 mg) + Sorbitol (2.5 g)LiquidIrrigationBaxter Laboratories1989-12-31Not applicableCanada
Leukosep - Solx A Additive SolutionMannitol (1.1 g/80mL) + Adenine (30 mg/80mL)SolutionIntravenousHaemonetics Corporation2013-05-15Not applicableUs
LeukoTrap SOLX A AdditiveMannitol (1.1 g/80mL) + Adenine (.03 g/80mL)SolutionIntravenousHaemonetics Corporation2015-11-12Not applicableUs
Sag-MMannitol (0.525 %) + Adenine (0.0169 %) + Glucose (0.9 %) + Sodium Chloride (0.877 %)SolutionUnknownHaemonetics CorporationNot applicableNot applicableCanada
Sag-mannitol SolutionMannitol (525 mg) + Adenine (16.9 mg) + D-glucose (818 mg) + Sodium Chloride (877 mg)SolutionUnknownLaboratorios Grifols s.a.Not applicableNot applicableCanada
Sorbitol Mannitol IrrigationMannitol (5.4 mg) + Sorbitol (27 mg)SolutionIrrigationIcu Medical Canada Inc1980-12-31Not applicableCanada
Sorbitol-MannitolMannitol (.54 g/100mL) + Sorbitol (2.7 g/100mL)IrrigantUrethralHospira, Inc.1980-02-22Not applicableUs
Categories
UNII
3OWL53L36A
CAS number
69-65-8
Weight
Average: 182.1718
Monoisotopic: 182.07903818
Chemical Formula
C6H14O6
InChI Key
FBPFZTCFMRRESA-KVTDHHQDSA-N
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
SMILES

Pharmacology

Indication

Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.

Structured Indications
Pharmacodynamics

Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.

Mechanism of action

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).

Absorption

Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.

Volume of distribution
Not Available
Protein binding

None

Metabolism

Mannitol is metabolized only slightly, if at all, to glycogen in the liver.

Route of elimination

It is rapidly excreted in the urine.

Half life

100 minutes

Clearance
Not Available
Toxicity

LD50=1700 mg/kg (rat oral)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.Approved
AclarubicinMannitol may increase the nephrotoxic activities of Aclarubicin.Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mannitol.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mannitol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Mannitol.Illicit
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Mannitol.Approved, Investigational
AmikacinMannitol may increase the nephrotoxic activities of Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mannitol.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Mannitol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Mannitol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Mannitol.Approved, Investigational
AmrubicinMannitol may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Mannitol is combined with Amyl Nitrite.Approved
annamycinMannitol may increase the nephrotoxic activities of annamycin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Mannitol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Mannitol is combined with Apraclonidine.Approved
ApramycinMannitol may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ArbekacinMannitol may increase the nephrotoxic activities of Arbekacin.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Mannitol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mannitol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mannitol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Mannitol.Experimental
BarbitalBarbital may increase the hypotensive activities of Mannitol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Mannitol.Approved
BekanamycinMannitol may increase the nephrotoxic activities of Bekanamycin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Mannitol.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mannitol.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Mannitol.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Mannitol is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mannitol.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mannitol.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mannitol.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan cilexetil.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Mannitol.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mannitol.Illicit, Investigational, Vet Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mannitol.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Mannitol.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Mannitol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Mannitol.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mannitol.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mannitol.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Mannitol.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.Approved
DaunorubicinMannitol may increase the nephrotoxic activities of Daunorubicin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Mannitol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mannitol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mannitol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mannitol.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mannitol.Approved, Investigational
DibekacinMannitol may increase the nephrotoxic activities of Dibekacin.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Diclofenamide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mannitol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.Experimental, Illicit
DihydrostreptomycinMannitol may increase the nephrotoxic activities of Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Mannitol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mannitol.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.Approved
DoxorubicinMannitol may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mannitol.Investigational
DuloxetineMannitol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Mannitol.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mannitol.Approved
EpirubicinMannitol may increase the nephrotoxic activities of Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Mannitol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mannitol.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mannitol.Illicit, Vet Approved
FelodipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Mannitol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mannitol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.Approved
FramycetinMannitol may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.Approved, Vet Approved
GeneticinMannitol may increase the nephrotoxic activities of Geneticin.Experimental
GentamicinMannitol may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1AMannitol may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GPX-150Mannitol may increase the nephrotoxic activities of GPX-150.Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Mannitol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mannitol.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Mannitol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mannitol.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.Approved, Illicit
Hygromycin BMannitol may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IdarubicinMannitol may increase the nephrotoxic activities of Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Mannitol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mannitol.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mannitol.Approved
IndapamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Mannitol.Withdrawn
INNO-206Mannitol may increase the nephrotoxic activities of INNO-206.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.Approved, Investigational
IsepamicinMannitol may increase the nephrotoxic activities of Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mannitol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mannitol.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mannitol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol.Approved
KanamycinMannitol may increase the nephrotoxic activities of Kanamycin.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mannitol.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Mannitol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Mannitol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Mannitol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Mannitol.Approved, Investigational
LevodopaMannitol may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mannitol.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mannitol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Mannitol.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mannitol.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Mannitol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved
LumacaftorThe serum concentration of Mannitol can be decreased when it is combined with Lumacaftor.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Mannitol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mannitol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mannitol.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Mannitol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Mannitol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Mannitol is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mannitol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mannitol.Approved, Investigational
MetrizamideMannitol may increase the nephrotoxic activities of Metrizamide.Approved
MicronomicinMannitol may increase the nephrotoxic activities of Micronomicin.Experimental
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mannitol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Mannitol.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Mannitol.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mannitol.Approved
NeamineMannitol may increase the nephrotoxic activities of Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.Approved, Investigational
NeomycinMannitol may increase the nephrotoxic activities of Neomycin.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Mannitol is combined with Nesiritide.Approved, Investigational
NetilmicinMannitol may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Mannitol.Experimental
NicorandilNicorandil may increase the hypotensive activities of Mannitol.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Mannitol.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Mannitol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mannitol.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mannitol.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mannitol.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Mannitol.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.Approved, Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mannitol.Approved, Illicit
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Mannitol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mannitol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mannitol.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mannitol.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.Approved
ParomomycinMannitol may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Mannitol.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mannitol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Mannitol.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mannitol.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Mannitol.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Mannitol.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Mannitol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Mannitol.Approved
PindololThe risk or severity of adverse effects can be increased when Mannitol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mannitol.Approved, Investigational
PirarubicinMannitol may increase the nephrotoxic activities of Pirarubicin.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Mannitol.Investigational
PlazomicinMannitol may increase the nephrotoxic activities of Plazomicin.Investigational
PlicamycinMannitol may increase the nephrotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Mannitol.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.Approved
PrimidonePrimidone may increase the hypotensive activities of Mannitol.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mannitol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.Approved, Investigational
PuromycinMannitol may increase the nephrotoxic activities of Puromycin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.Approved
RanolazineThe serum concentration of Mannitol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mannitol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mannitol.Approved, Investigational
RibostamycinMannitol may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Mannitol is combined with Riociguat.Approved
RisperidoneMannitol may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Mannitol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mannitol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Mannitol.Approved
SabarubicinMannitol may increase the nephrotoxic activities of Sabarubicin.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mannitol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Mannitol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mannitol.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mannitol.Approved, Vet Approved
SisomicinMannitol may increase the nephrotoxic activities of Sisomicin.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Mannitol.Approved
Sodium phosphateMannitol may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.Approved
SP1049CMannitol may increase the nephrotoxic activities of SP1049C.Investigational
SpectinomycinMannitol may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational, Vet Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.Approved, Investigational
StreptomycinMannitol may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
StreptozocinMannitol may increase the nephrotoxic activities of Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Mannitol.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mannitol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mannitol.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Mannitol.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Mannitol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mannitol.Approved, Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Mannitol.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Mannitol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.Approved
TobramycinMannitol may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Mannitol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mannitol.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mannitol.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Mannitol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.Approved
ValrubicinMannitol may increase the nephrotoxic activities of Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.Approved
Zoptarelin doxorubicinMannitol may increase the nephrotoxic activities of Zoptarelin doxorubicin.Investigational
ZorubicinMannitol may increase the nephrotoxic activities of Zorubicin.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Walter M. Kruse, "Process for preparing mannitol from glucose." U.S. Patent US4029878, issued August, 1956.

US4029878
General References
  1. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: a randomized trial. Neurosurgery. 2001 Oct;49(4):864-71. [PubMed:11564247]
  2. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery. 2002 Sep;51(3):628-37; discussion 637-8. [PubMed:12188940]
  3. Cruz J, Minoja G, Okuchi K, Facco E: Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83. [PubMed:15035271]
  4. Roberts I, Smith R, Evans S: Doubts over head injury studies. BMJ. 2007 Feb 24;334(7590):392-4. [PubMed:17322250]
  5. Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001049. [PubMed:16235278]
  6. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187]
External Links
Human Metabolome Database
HMDB00765
KEGG Drug
D00062
KEGG Compound
C00392
PubChem Compound
6251
PubChem Substance
46506446
ChemSpider
6015
BindingDB
50142798
ChEBI
16899
ChEMBL
CHEMBL689
Therapeutic Targets Database
DAP000874
PharmGKB
PA450320
HET
MTL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mannitol
ATC Codes
B05BC01 — MannitolB05CX04 — MannitolA06AD16 — MannitolR05CB16 — Mannitol
AHFS Codes
  • 40:36.00 — Irrigating Solutions
  • 36:40.00 — Kidney Function
  • 40:28.12 — Osmotic Diuretics
PDB Entries
1m2w / 1p6k / 1rs6 / 1rs7 / 1zzq / 1zzu / 2vfu / 3n62 / 3n65 / 3n66
show 6 more
FDA label
Download (50 KB)
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceAllergies / Asthma Bronchial / Lung Diseases, Obstructive / Reactive Airways Disease (RAD)1
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedTreatmentCystic Fibrosis (CF)2
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPain1
1TerminatedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Long-Term Effects Secondary to Cancer Therapy in Children1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedNot AvailableBronchiectasis1
1, 2CompletedPreventionAcute Gastroenteritis / Norwalk Virus Infection1
1, 2RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Oligoastrocytoma / Recurrent Adult Brain Neoplasm1
1, 2RecruitingTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Adult Ependymoblastoma / Adult Medulloblastoma / Adult Pineoblastoma / Adult Supratentorial Embryonal Tumor, Not Otherwise Specified / Adult Supratentorial Primitive Neuroectodermal Tumor / Atypical Teratoid/Rhabdoid Tumor / Central Nervous System Embryonal Tumor / Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Childhood Ependymoblastoma / Germ Cell Tumors / Medulloepithelioma / Ototoxicity / Recurrent Adult Brain Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
1, 2RecruitingTreatmentCentral Nervous System Lymphoma1
1, 2RecruitingTreatmentDiabetic Peripheral Neuropathy (DPN)1
1, 2RecruitingTreatmentPostherpetic Neuralgia1
1, 2Unknown StatusTreatmentSevere Head Trauma1
1, 2WithdrawnNot AvailableEndothelial Dysfunction / Insulin Resistance1
1, 2WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Exacerbation1
2Active Not RecruitingOtherIntra-dialytic Hypotension1
2Active Not RecruitingTreatmentRadiation Necrosis1
2CompletedBasic ScienceHealthy Volunteers2
2CompletedPreventionAcute Renal Failure (ARF) / Mortality / Renal Dysfunction1
2CompletedPreventionCisplatin Nephrotoxicity1
2CompletedTreatmentCystic Fibrosis (CF)3
2CompletedTreatmentOpioid Dependence1
2RecruitingTreatmentAlcohol Use Disorder (AUD)1
2Unknown StatusTreatmentCystic Fibrosis (CF) / Pneumonia1
2Unknown StatusTreatmentStrokes1
2WithdrawnTreatmentAcute Cerebrovascular Accidents / Edema of the cerebrum1
2, 3TerminatedTreatmentIntracranial Pressure Increase / Severe Trauma Brain Injury1
3Active Not RecruitingTreatmentRenal Cancers1
3CompletedDiagnosticAsthma Bronchial1
3CompletedTreatmentBronchiectasis2
3CompletedTreatmentCystic Fibrosis (CF)1
3CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3CompletedTreatmentWheezing1
3Not Yet RecruitingTreatmentCiguatoxin1
3RecruitingTreatmentKidney Transplantation, Mannitol1
3TerminatedTreatmentAcute Ischemic Stroke (AIS)1
3TerminatedTreatmentDopamine Beta Hydroxylase Deficiency / Multiple Systems Atrophy / Parkinson's Disease (PD) / Progressive autonomic failure / Symptomatic Neurogenic Orthostatic Hypotension1
3TerminatedTreatmentElevated Intracranial Pressure / Traumatic Brain Injury (TBI)1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3Unknown StatusTreatmentFetal Hypoxia / Reperfusion Injury1
3Unknown StatusTreatmentMalaria, Cerebral1
4CompletedNot AvailableBowel preparation therapy1
4CompletedNot AvailableBrain Swelling1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticFood Allergy1
4CompletedDiagnosticUreteral Patency1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentIntracranial Pressure Increase1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4TerminatedNot AvailableIntracranial Pressure Increase / Traumatic Brain Injury (TBI)1
4Unknown StatusTreatmentIntracranial Pressure / Osmotherapy1
4Unknown StatusTreatmentRetinopathy, Diabetic1
Not AvailableCompletedNot AvailableProstate Cancer1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic SciencePain1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedPreventionIntraocular Pressure Change in Intravitreal Injection1
Not AvailableCompletedTreatmentFulminant Hepatic Failure1
Not AvailableCompletedTreatmentHand, Foot, and Mouth Disease1
Not AvailableCompletedTreatmentIntracranial Pressure / Neoplasms, Brain1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableRecruitingBasic ScienceAsthma Bronchial1
Not AvailableRecruitingBasic ScienceCystic Fibrosis (CF)1
Not AvailableRecruitingTreatmentFulminant Hepatic Failure1
Not AvailableRecruitingTreatmentNeoplasms, Kidney1
Not AvailableWithdrawnTreatmentElevated Intracranial Pressure1
Not AvailableWithdrawnTreatmentTraumatic Brain Injury (TBI)1

Pharmacoeconomics

Manufacturers
  • B braun medical inc
  • Hospira inc
  • Miles laboratories inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • International medication system
  • Luitpold pharmaceuticals inc
  • Merck and co inc
  • Watson laboratories inc
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
CapsuleRespiratory (inhalation)40 mg
LiquidIrrigation
LiquidTopical.1 g/2mL
SolutionIntravenous
Injection, solutionIntravenous10 g/100mL
Injection, solutionIntravenous12.5 g/50mL
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous250 mg/mL
Injection, solutionIntravenous5 g/100mL
IrrigantIrrigation5 g/100mL
SolutionIntravenous250 mg
LiquidIntravenous100 mg
LiquidIntravenous250 mg
LiquidIntravenous50 mg
SolutionIntravenous200 mg
Injection, solutionIntravenous15 g/100mL
LiquidIntravenous10 g
SolutionIntravenous20 g
LiquidIrrigation5 %
SolutionUnknown
SolutionIrrigation
IrrigantUrethral
Prices
Unit descriptionCostUnit
Osmitrol 20% iv solution0.15USD ml
Osmitrol 10% iv solution0.07USD ml
Osmitrol 15% iv solution0.07USD ml
Mannitol powder0.05USD g
Mannitol 15% iv solution0.04USD ml
Mannitol 20% iv solution0.04USD ml
Mannitol 25% vial0.03USD ml
Osmitrol 5% iv solution0.03USD ml
Mannitol 10% iv solution0.02USD ml
Mannitol 5% iv solution0.02USD ml
Resectisol 5% solution0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168 °CPhysProp
boiling point (°C)290-295 °C at 3.50E+00 mm HgPhysProp
water solubility2.16E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-3.10HANSCH,C ET AL. (1995)
Caco2 permeability-6.21ADME Research, USCD
pKa13.5 (at 25 °C)BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-3.7ChemAxon
logS0.1ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area121.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity38.4 m3·mol-1ChemAxon
Polarizability17.04 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6525
Blood Brain Barrier-0.5997
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.662
P-glycoprotein inhibitor INon-inhibitor0.9535
P-glycoprotein inhibitor IINon-inhibitor0.9551
Renal organic cation transporterNon-inhibitor0.9252
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.878
CYP450 3A4 substrateNon-substrate0.7431
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9419
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9232
CYP450 3A4 inhibitorNon-inhibitor0.9402
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.958
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7823
BiodegradationReady biodegradable0.8595
Rat acute toxicity1.1260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.9329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.14 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (6 TMS)GC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MS (6 TMS)GC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0229-9100000000-5655e9df8e0fdcaa72a0
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9200000000-0dad802ab0000303cb33
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MSGC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-f4df881aeebac32de5c7
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-014j-9600000000-26f4335f7ef7c81ca261
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-066r-9000000000-73db1fbd51fb8c061bec
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-05mo-9000000000-45a4dea1d21286c4b8da
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0089-6900000000-961d76d6550bc342ffa1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0089-6900000000-061f88989a6ac71321e3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0ik9-1900000000-eb8ea056f3b1dfe2fb1f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-1900000000-6768b4744e1a4e56b18b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kb-1900000000-0765563624accf132d03
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00dr-0900000000-e159f4e76b7847313f35
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0900-0910000000-8d56394cbc78dd3b5ca0
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0079-0900000000-63517bff4abfbf09e1ca
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0w2l-0940000000-dc20c851073dcbc4dba9
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar alcohols
Alternative Parents
Monosaccharides / Secondary alcohols / Polyols / Primary alcohols / Hydrocarbon derivatives
Substituents
Sugar alcohol / Monosaccharide / Secondary alcohol / Polyol / Hydrocarbon derivative / Primary alcohol / Alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
mannitol (CHEBI:16899)

Enzymes

Kind
Protein
Organism
Pseudomonas fluorescens
Pharmacological action
Unknown
Actions
Substrate
General Function
Nucleotide binding
Specific Function
Not Available
Gene Name
mtlD
Uniprot ID
O08355
Uniprot Name
Mannitol dehydrogenase
Molecular Weight
54497.41 Da
References
  1. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34